SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Sexual HealthResearch peptide

PT-141

aka Bremelanotide

A melanocortin-receptor agonist studied (and approved in some regions) for sexual dysfunction in both men and women.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

PT-141 is a synthetic peptide derived from melanotan II, modified to act on melanocortin receptors involved in sexual arousal pathways.

Source
  • Pharmaceutical manufacturing (FDA-approved as bremelanotide)
Forms
  • Subcutaneous injection
  • Intranasal spray (research)

Mechanism of action

Activates melanocortin receptors (especially MC4R) in the central nervous system to enhance sexual arousal, independent of vascular mechanisms.

Pathways
  • · MC4R activation in hypothalamus
  • · Central arousal signaling
Receptors
  • · MC4R
  • · MC3R

How it acts on the body

PT-141 is unique among arousal-targeting compounds because it works centrally rather than vascularly. PDE5 inhibitors like sildenafil enhance the downstream plumbing of arousal (blood flow); PT-141 activates the original signal in the brain. It binds MC4R in the medial preoptic area of the hypothalamus — the same circuit that natural arousal cues activate — so it produces desire and responsiveness rather than just mechanical capability.

Because it operates upstream of vascular signaling, it can work in cases where blood-flow drugs fail, and conversely it can be ineffective if the underlying issue is purely vascular. The melanocortin system also touches appetite suppression, blood-pressure regulation, and pigmentation, which is why nausea, transient blood-pressure elevation, and freckling are characteristic side effects.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

Melanocortin signaling (MC4R)Increases
Central hypothalamic arousal pathway activated within ~45 minutes.
OxytocinIncreases
Indirectly raised via downstream activation of paraventricular nucleus.
Dopamine (limbic)Modulates
Increases dopaminergic activity in arousal-related circuits.
NorepinephrineIncreases
Transient sympathetic activation drives mild blood-pressure rise.
Sex steroids (testosterone, estrogen)Stabilizes
No direct effect on circulating sex hormones.

Effects on the body

Increases
Sexual arousal and desire
Supports
Erectile and lubrication responses centrally

Organ system effects

Brain & CNS

Acts on hypothalamic arousal circuits.

Reproductive

Improves arousal and response in both sexes.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Approved for hypoactive sexual desire disorder in some regions
  • Works centrally — useful when vascular medications are not effective
  • Effective within 30–60 minutes of dosing

Potential side effects

Common
  • · Nausea
  • · Flushing
  • · Headache
  • · Transient blood-pressure elevation
Rare
  • · Darkening of skin/freckles with frequent use
  • · Vomiting
Serious
  • · Cardiovascular events in those with uncontrolled hypertension

Drug interactions

Antihypertensives
Can transiently raise blood pressure.
moderate
Naltrexone
May interfere via overlapping CNS pathways.
moderate

Pairing context

Often combined with
  • PDE5 inhibitors
    Different mechanism; can be complementary under medical supervision.
Avoid combining with
  • Uncontrolled hypertension
    Risk of acute BP elevation.
  • Cardiovascular disease
    Avoid until cleared by a clinician.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.